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Background: Breast cancer prognosis can be adversely influenced by obesity, physical inactivity and metabolic
dysfunction. Interventions aimed at improving surrogate markers of breast cancer risk such as insulin resistance may
result in improved breast cancer outcomes. The design of such interventions may be improved through increased
understanding of metabolic presentation in this cohort. This cross-sectional study aimed to characterise the
metabolic profile of breast cancer survivors relative to abdominal obesity and insulin resistance. A secondary aim
was to compare measures of energy output across these groups.
Methods: Sixty-nine women (mean (SD) age 53.43 (9.39) years) who had completed adjuvant chemotherapy and
radiotherapy for breast cancer were recruited. All measures were completed during one assessment conducted
3.1 (1.0) years post diagnosis. Body composition was measured by bioimpedance analysis and waist circumference
(WC). Fasting (12 hour) blood samples were drawn to measure lipid profile, glucose, insulin, glycosylated
haemoglobin A1c (HBA1c) and C-reactive protein (CRP). Insulin resistance was estimated by the homeostatic model
assessment index (HOMA-IR)). Energy output was evaluated by resting metabolic rate (RMR) measured by indirect
calorimetry and physical activity measured by accelerometry. Characteristics were compared across four groups
(1. WC <80 cm, not insulin resistant; 2. WC 80–87.9 cm, not insulin resistant; 3. WC >88 cm, not insulin resistant;
4. WC >80 cm, insulin resistant) using ANOVA (p < 0.05).
Results: Group 4 was characterised by significant disturbances in measures of glucose metabolism (glucose, insulin,
HOMA-IR and HBA1c) and raised CRP compared to other groups. Group 4 also displayed evidence of dyslipidemia
and higher body composition values compared to Groups 1 and 2. Both absolute and adjusted RMR were
significantly higher in the Group 4 versus all other groups. Physical activity levels were similar for all groups.
Conclusions: The results from this study suggest that participants who were both centrally obese and insulin
resistant showed evidence of dyslipidemia, low-grade inflammation and glucose dysregulation. Metabolic profiles of
participants who were centrally obese only were not significantly different from lean participants. Consideration of
baseline metabolic presentation may be useful when considering the therapeutic targets for future interventions in
this cohort.
Keywords: Breast cancer, Insulin resistance, Metabolic syndrome, Resting metabolic rate, Physical activity, Prognosis* Correspondence: emguinan@tcd.ie
1Discipline of Physiotherapy, School of Medicine, Trinity Centre for Health
Sciences, St. James’s Hospital, Dublin 8, Ireland
Full list of author information is available at the end of the article
© 2013 Guinan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Guinan et al. Nutrition Journal 2013, 12:99 Page 2 of 9
http://www.nutritionj.com/content/12/1/99Introduction
Metabolic dysfunction, including the metabolic syndrome
(MetSyn) and insulin resistance, is a long-term complica-
tion of curative treatment for many cancers including
breast [1], prostate [2] and testicular [2]. There is increas-
ing evidence that metabolic disturbance, characterised by
insulin resistance [3,4], altered adipokines [3] and chronic
low-grade inflammation [5], is associated with increased
breast cancer and all-cause mortality and a higher risk of
breast cancer recurrence. Breast cancer survivors repre-
sent a unique group who endure several treatment associ-
ated alterations in lifestyle habits including weight gain [6]
and reduced physical activity levels [7], along with high
risk of ovarian failure in premenopausal women [8], lead-
ing to early onset menopause and consequential worsen-
ing metabolic profiles [9]. However, not all breast cancer
survivors are overweight and inactive and not all over-
weight and obese women are metabolically unhealthy [10].
The presentation of metabolic disturbance varies greatly
among obese individuals [11] and there is a need for
greater understanding of the characteristics of metabolic
dysfunction in breast cancer survivors in order to design
targeted weight-loss and exercise interventions.
The classification of metabolically unhealthy has not
been standardised due to the ever-evolving definition of
the MetSyn and the ongoing debate regarding the inclu-
sion of a measure of insulin resistance in the syndrome
definition [12-14]. The current MetSyn definition in-
cludes central obesity, elevated fasting glucose, athero-
genic dyslipidemia and hypertension [12]. Insulin
resistance is a central component of the MetSyn and is
arguably one of the most important features of meta-
bolic dysfunction in relation to cancer due to the mito-
genic effects of insulin on breast cancer cells [15] and
the substantial evidence linking hyperinsulinemia and in-
sulin resistance to cancer prognosis [3]. Equally central
obesity, characterised by increased visceral fat accumula-
tion, is considered a core component of the MetSyn and
is associated with the secretion of many pro-tumour
products including pro-inflammatory cytokines (inter-
leukin (IL)-6 and tumor necrosis factor (TNF)-α),
adipokines and sex hormones [16]. There is a lack of
consensus regarding the cut-point for central obesity, as
measured by waist circumference (WC). Generally,
80 cm is the accepted cut-point for central obesity in
women while ≥88 cm is associated with substantially in-
creased disease risk [12]. While most individuals with
the MetSyn are also insulin resistant [13], the relation-
ship between insulin resistance and atherogenic
dyslipidemia and hypertension is unclear, particularly
due to the inclusion of drug therapies for lipid abnor-
malities and hypertension in the most recent MetSyn
definition. In breast cancer survivors, it may be useful to
examine metabolic dysfunction in terms of insulinresistance and visceral obesity as these measures may be
potentially more predictive of cancer-specific outcome.
Long-term obesity is essentially due to an imbalance
between energy intake and energy output. Resting meta-
bolic rate (RMR) is the largest component of energy ex-
penditure [17] and has been shown to be altered in the
presence of metabolic abnormalities [18]. Equally habit-
ual physical activity, which represents up to 15% of total
energy expenditure, is a key factor in the development
and management of the MetSyn [14] and may positively
influence breast cancer prognosis [19]. The aim of the
current study was to characterise the metabolic profiles
of breast cancer relative to worsening central obesity
and insulin resistance. A secondary aim was to compare
energy output across these groups and to examine asso-
ciations between energy expenditure and metabolic
parameters.
Methods
Study design and participants
The study was designed as a cross-sectional study. A
convenience sample of breast cancer survivors were
recruited from oncology clinics at St. James’s Hospital,
Dublin Ireland from May 2011 to June 2012. Participants
were eligible for the study if they had completed all adju-
vant breast cancer treatment including at least one of
the following: chemotherapy, radiotherapy and anti Her-2
directed biological therapy. Those continuing to take
adjuvant hormonal therapy were eligible to participate.
Evidence of active or recurrent disease, co-morbidities in-
cluding type II diabetes mellitus (T2DM) or age >70 years
were considered exclusion criteria. Ethical approval was
granted by the hospital research ethics committee and all
participants provided written, informed consent prior to
measurements.
Data collection
Body composition, including body weight, percentage
body fat and fat free mass (FFM), was estimated by
bioimpedance analysis using the Tanita MC 180 MA
Multi-Frequency Body Composition Analyzer (Tanita
Corp, Tokyo, Japan). Standing height was measured
barefoot to the nearest millimetre using a SECA
stadiometer. WC was measured using a flexible measur-
ing tape, in duplicate, to the nearest millimetre, at the
midpoint between the top of the iliac crest and the last
rib [20]. Blood pressure measurements were taken on
the non-surgical side in duplicate using the auscultatory
method. Fasting (12 hour) venous blood samples were
drawn to measure glucose, insulin, lipid profile (total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C)
and triglycerides (TG)), (glycosylated haemoglobin A1c
(HBA1c)) and C–Reactive Protein (CRP). Insulin
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Assessment Index (HOMA-IR): [(fasting glucose (mmol.L-1)
× fasting insulin (mU.L-1)/22.5] [21]. Insulin resistance was
defined as the 75th percentile of HOMA-IR of participants
studied (HOMA-IR = 2.45) [22]. The MetSyn was diag-
nosed in the presence of any three of the following:
elevated WC (≥80 cm); elevated TG (≥1.7 mmol.L-1) or
drug therapy for lipid abnormalities; reduced HDL-C
(<1.3 mmol.L-1) or drug therapy for lipid abnormalities;
elevated blood pressure (systolic ≥130 mmHg and/or
diastolic ≥85 mmHg) or antihypertensive medication;
elevated fasting glucose (≥5.6 mmol.L-1) or glucose-
lowering medication [12].
Insulin was measured by electrochemiluminescence
immunoassay (Elecsys Insulin Assay, Roche Dianostics
GMBH). Enzymatic, colorimetric assays (Roche/Hitachi
cobas c systems) were used to measure fasting glucose,
TC, HDL-C and TG. LDL was calculated using the
Friedewald equation. High performance liquid chroma-
tography (Arkray/Adams A1c HA-8160 Analyser System)
was used to measure HBA1c and CRP was measured by
particle enhanced immunoturbidimetric assay (Roche/
Hitachi cobas c systems). Laboratory analyses were car-
ried out at the national biochemistry reference labora-
tory at St. James’s Hospital, Dublin.
Energy output was measured by RMR and habitual
physical activity. RMR and respiratory quotient (RQ)
were measured by indirect calorimetry using the
COSMED Metabolic Quart according to the guidelines
of Compher and colleagues [23]. Measurements were
completed with the participant in the supine position
following a 10–20 minute rest period. Respiratory gas
exchange was measured continuously for 20 minutes,
excluding the first five minutes of data, using a canopy
collection device. Data was obtained from at least 5
minutes of a stable measurement (coefficient of variation
<10% (variation in oxygen consumption (VO2) ≤10%;
variation in carbon dioxide production (VCO2) ≤10%).
RMR was expressed in absolute values (kJ.day-1) and as
RMR adjusted for FFM (kJ.day-1.kg-1) [24]. Physical
activity was measured objectively using the RT3 activity
monitor (Stayhealthy Inc Montrovia, CA, USA). The
RT3 is a valid [25], reliable [26] tool and was used to
quantify percentage time spent in each domain of activity
and to monitor adherence to physical activity guidelines
(≥30 minutes of moderate intensity activity, accumulated
in ≥10 minute bouts, five days per week [27]). Activity
intensity was defined using validated cut-points [25] and
sedentary behaviour was defined as an activity count ≤100
[28]. Habitual activity patterns in the preceding year
were measured subjectively using the Minnesota Leisure
Time Physical Activity Questionnaire (MLTPAQ). The
MLTPAQ is a valid [29] interview-administered ques-
tionnaire designed to measure the frequency of leisure-time and recreational activities in the preceding year
and combines this information with intensity scores to
measure physical activity in terms of activity metabolic
index (AMI) and expressed as metabolic equivalent
(MET)-minutes per day (MET-min.day-1).
Data was analysed using SPSS version 18.0 software
(SPSS, Inc, Evanstron, IL). Distributions were checked
for normality using the K-S test and log-transformations
were applied to non-normally distributed data. Data are
presented as mean ± standard deviation. Participants
were classed into four subgroups: Group 1: healthy WC
(<80 cm) and not insulin resistant; Group 2: elevated WC
(WC 80–87.9 cm) and were not insulin resistant; Group 3:
substantially increased waist circumference (WC >88 cm)
and not insulin resistant; and Group 4: both centrally
obese and insulin resistant. With the exception of one
participant who had a waist circumference of 82.4 cm, all
women in Group 4 had a WC >88 cm. Anthropometric,
metabolic and energy output variables were compared
between the four groups using analysis of variance
(ANOVA). Significance was set at p < 0.05. Post hoc ana-
lysis was completed using Tukey’s HSD method when a
significant group effect was observed. Kruskal-Wallis non-
parametric ANOVA was used to compare distributions
between non-parametric data (BMI, glucose, HBA1c and
CRP) and post hoc analysis was completed using Mann–
Whitney U test for comparison between pairs of group
Corrections were made for multiple comparisons using
the bonferroni correction (p < 0.01). Correlations between
energy output and metabolic variables were examined
using Pearson Product Moment Correlation Coefficients
(PPMCC) for normally distributed data and Spearman’s
rho for non-normally distributed data. The lowest detect-
able value for CRP was 1 mg.L-1 and therefore results
<1 mg.L-1 were assigned a value of 1 mg.L-1. Values
>15 mg.L-1 were excluded these most likely represented
an acute inflammatory event [30].
Results
Sixty nine participants (mean (SD) age 53.43 (9.39))
entered the study. The mean time since diagnosis for the
overall group was 3.1 (1.0) years. Participant demograph-
ics and treatment details are shown in Table 1. Groups
were similar for all demographics (p > 0.05). The major-
ity of participants were treated with adjuvant chemo-
therapy using standard anthracycline and taxane based
regimens. Almost 80% of the group were taking adjuvant
hormonal therapy.
Anthropometric and metabolic parameters are shown in
Table 2. Women in Group 3 and Group 4 demonstrated
significantly higher anthropometric measures, characterised
by significantly greater body weight (p < 0.001 vs. Group 1
and p < 0.002 vs. Group 2), BMI (p < 0.001 for both), WC
(p < 0.001 for both) and percentage body fat (p < 0.001 for
Table 1 Participant demographics
Characteristic Group 1 (n = 19) Group 2 (n = 16) Group 3 (n = 16) Group 4 (n = 18)
Participant demographics
Age (years) 52.04 (11.7) 50.27 (8.48) 55.65 (9.49) 55.59 (6.69)
Time since diagnosis (years) 3.39 (0.90) 2.69 (0.92) 3.19 (0.85) 3.14 (1.22)
Menopausal status*
Premenopausal 11 (58%) 11 (69%) 8 (50%) 8 (44%)
Postmenopausal 8 (42%) 5 (31%) 8 (50%) 10 (56%)
Marital status
Married 16 (84%) 10 (63%) 11 (69%) 11 (61%)
Single 3 (16%) 6 (37%) 5 (31%) 5 (39%)
Smoking history
Current smoker 1 (5%) 9 (56%) 2 (13%) 6 (33%)
Cancer details
Cancer stage
I 6 (32%) 4 (25%) 5 (31%) 4 (22%)
II 9 (47%) 9 (56%) 8 (50%) 10 (56%)
III 4 (21%) 3 (19%) 3 (19%) 4 (22%)
Estrogen receptor positive 14 (74%) 14 (88%) 14 (88%) 14 (78%)
Surgery
Wide local excision 9 (47%) 5 (31%) 10 (63%) 7 (39%)
Mastectomy 10 (53%) 11 (69%) 6 (38%) 11 (61%)
Axillary clearance 7 (37%) 9 (38%) 4 (25%) 10 (56%)
Chemotherapy 17 (90) 14 (88%) 13 (81%) 16 (89%)
Radiotherapy 15 (79) 11 (69%) 14 (88%) 16 (89%)
Hormone therapy
Tamoxifen 9 (47%) 7 (44%) 12 (75%) 7 (39%)
Aromatase inhibitor 5 (26%) 6 (38%) 2 (13%) 7 (39%)
Biological therapy
Herceptin 3 (16%) 2 (13%) 1 (6%) 2 (11%)
Data are presented as mean (standard deviation) for continuous variables and as frequency (percentage) for categorical variables.
*Refers to menopausal status at diagnosis.
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significantly higher in both Group 3 (p = 0.002) and Group
4 (p = 0.001) compared to Group 1. Metabolic profiles
were significantly worse in Group 4 than other groups
characterised by significantly lower HDL-C (Group 4 vs.
Group 1 p = 0.02; vs. Group 2 p = 0.008), elevated TG
(Group 4 vs. Group 1 p < 0.001; vs. Group 2 p = 0.009),
measures of insulin-glucose metabolism (fasting glucose,
fasting insulin, HOMA-IR and HBA1c, p < 0.001 vs. all
groups) and raised CRP (Group 4 vs. Group 1 p < 0.001; vs.
Group 2 p = 0.005; vs. Group 3 p = 0.01). Metabolic profiles
did not vary between non-insulin-resistant groups.
Energy output variables across the four groups are
presented in Table 3. Absolute RMR (kJ.day-1) was
significantly higher in Group 4 compared to all othergroups (vs. Group 1 p < 0.001, vs. Group 2 p = 0.005
and vs. Group 3 p = 0.05). Results remained significant
when RMR was adjusted for FFM (kJ.day-1.kg-1)
(Group 4 vs. Group 1 p < 0.001; vs. Group 2 p = 0.005;
vs. Group 3 p = 0.05). Adjusted RMR was significantly
correlated with a number of metabolic features including
WC (r = 0.32; p < 0.01), HOMA-IR (r = 0.48; p < 0.001),
CRP (rho = 0.31; p = 0.02), HDL-C (r = −0.31; p = 0.02),
TG (r = 0.34; p = 0.009). Adjusted RMR was not correlated
with either measure of glucose metabolism (glucose or
HBA1c) or blood pressure. Neither objective nor subject-
ive habitual activity varied between groups. Regardless of
whether measured by objective or subjective methods,
physical activity did not display any correlations with
metabolic parameters.
Table 2 Comparison of anthropometric and metabolic variables across groups
Characteristic Group 1 (n = 19) Group 2 (n = 16) Group 3 (n = 16) Group 4 (n = 18)
Age (years) 52.16 (11.69) 50.37 (8.52) 55.56 (9.42) 55.61 (6.77)
Anthropometry
Body weight (kg) 59.73 (6.76) 66.22 (5.68) 79.55 (12.58)a, b 79.61 (13.85)a, b
BMI (kg.m-2) 23.09 (21.7-24.6) 24.86 (23.5-26.6)a 30.21 (27.5-32.0)a, b 30.84 (26.0-36.3)a, b
BMI categories
Healthy weight (18.5-24.9 kg.m-2) 17 (90%) 8 (50%) 0 1 (6%)
Overweight (25–29.9 kg.m-2) 2 (10%) 8 (50%) 10 (62%) 8 (44%)
Obese (> 30 kg.m-2) 0 0 6 (38%) 9 (50%)
Waist circumference (cm) 74.05 (4.65) 83.20 (2.54)a 95.18 (6.56)a, b 97.45 (10.57)a, b
Percentage body fat (%) 31.15 (3.69) 33.41 (3.08) 40.37 (3.04)a, b 40.19 (5.21)a, b
Fat free mass (kg) 40.978 (3.59) 44.08 (4.19) 47.22 (5.77)a 47.12 (5.37)a
Blood pressure
Systolic blood pressure (mmHg) 114.74 (15.57) 117.00 (9.39) 119.09 (9.98) 125.92 (13.49)
Diastolic blood pressure (mmHg) 77.29 (9.96) 75.69 (4.79) 78.50 (8.73) 80.56 (7.91)
Hypertensive (BP >130/85 mmHg) 4 (21%) 2 (13%) 5 (31%) 9 (50%)
Anti-hypertensive medication 2 (10%) 2 (13%) 4 (25%) 6 (33%)
Lipid profile
TC (mmol.L-1) 5.24 (0.98) 5.33 (1.09) 4.61 (0.53) 5.33 (0.93)
Dyslipidemia (TC > 5.2 mmol.L-1) 9 (47) 9 (56) 3 (19) 9 (50)
HDLC (mmol.L-1) 1.83 (0.41) 1.89 (0.51) 1.62 (0.36) 1.40 (0.41)a, b
LDLC (mmol.L-1) 2.98 (0.78) 3.13 (1.32) 2.38 (0.67) 3.11 (0.89)
TG (mmol.L-1) 0.92 (0.68-1.09) 1.07 (0.7-1.4) 1.16 (0.8-1.6) 1.46 (1.0-1.8)a, b
Cholesterol medications 0 1 (6%) 3 (19%) 0
Glucose metabolism
Fasting glucose (mg.dL-1) 4.72 (4.3-5.0) 4.81 (4.7-5.0) 4.86 (4.6-5.2) 5.32 (4.8-5.5)a, b, c
Fasting insulin (mU.L-1) 6.73 (5.5-6.9) 7.30 (5.7-9.8) 8.38 (7.3-9.6) 14.49 (11.6-19.4)a, b, c
Hyperinsulinemia (>12 mU.L-1) 0 0 1 (6%) 14 (78%)
Insulin resistance (HOMA-IR) 1.42 (1.1-1.8) 1.61 (1.2-2.1) 1.81 (1.4-2.1) 3.43 (2.5-4.2)a, b, c
HBA1c (mmol.mol-1) 35.21 (33.0-38.0) 35.25 (33.5-37.0) 35.75 (34.0-37.0) 38.39 (33.5-41.0)a, b
Glucose medications 0 0 0 0
Inflammatory marker
CRP (mg.L-1) 1.53 (1.0-1.8) 1.89 (1.0-2.2) 2.09 (1.1-2.4) 4.98 (1.4-7.0)a, b, c
Metabolic syndrome 0 3 (19%) 5 (31%) 12 (67%)
Data are displayed as mean (± standard deviation) for normally distributed variables and median (inter-quartile range) for non-normally distributed variables and
as frequency (percentage) for categorical variables. Abbreviations: kg kilogram, BMI body mass index, TC total cholesterol, HDL-C high density lipoprotein
cholesterol, LDL-C low density lipoprotein cholesterol, TG triglycerides, HOMA-IR homeostatic model assessment index, HBA1c glycosylated haemoglobin A1c,
CRP C - reactive protein.
a = significantly different from Group 1; b = significantly different from Group 2; c = significantly different from Group 3.
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Results demonstrate that breast cancer survivors, who
are both centrally obese and insulin resistant, are
characterised by greater metabolic dysfunction in terms
of dyslipidemia, glucose dysmetabolism, raised CRP and
a higher prevalence of the MetSyn compared to women
who are centrally obese in the absence of insulin resist-
ance. This altered metabolic profile was accompanied by
higher absolute and adjusted RMR levels but was notassociated with differing habitual physical activity levels.
These results are consistent with others which have
demonstrated deteriorations in lipid-lipoprotein profile,
inflammatory status and measures of glucose-insulin
homeostasis when central obesity exists concurrently
with insulin resistance [31,32]. In these studies, partici-
pants who were centrally obese and not insulin resistant
were characterised by metabolic profiles that were simi-
lar to lean controls.
Table 3 Comparison of energy output variables across groups
Characteristic Group 1 (n = 19) Group 2 (n = 16) Group 3 (n = 16) Group 4 (n = 18)
Resting metabolic rate
RMR (kJ.day-1) 4884.59 (619.37) 5232.79 (438.65) 5484.26 (625.03) 6190.93 (959.43)a, b, c
Adjusted RMR (kJ.day-1.kg-1) 111.7 (12.5) 112.9 (7.6) 110.5 (11.7) 122.3 (10.7) a, b, c
RQ (VCO2/VO2) 0.77 (0.74-0.82) 0.75 (0.72-0.77) 0.76 (0.72-0.83) 0.79 (0.76-0.85)
Physical activity
RT3 activity monitor
Sedentary (min.day-1) 374.73 (86.55) 414.06 (104.19) 456.38 (98.89) 412.88 (103.94)
Light intensity (min.day-1) 390.19 (87.51) 346.31 (55.74) 346.91 (85.76) 380.26 (61.28)
Moderate intensity (min.day-1) 56.46 (18.0-81.4) 47.40 (17.8-76.7) 34.91 (20.1-48.6) 45.48 (28.8-54.5)
Vigorous intensity (min.day-1) 25.22 (3.0-37.2) 20.37 (2.1-46.1) 8.94 (0.7-9.9) 11.54 (0.4-28.8)
Minnesota LTPAQ
Light AMI (MET-h.week-1) 0 0 0 0
Moderate AMI(MET-h.week-1) 14.0 (13.1) 16.7 (18.8) 12.3 (9.5) 13.7 (9.0)
Vigorous AMI (MET-h.week-1) 2.8 (6.4) 1.0 (2.9) 2.0 (7.6) 0.4 (6.9)
Total AMI (MET-h.week-1) 24.4 (17.3) 20.1 (21.3) 16.3 (15.6) 15.1 (18.8)
Adherence to PA guidelines 6 (32%) 5 (31%) 3 (19%) 3 (17%)
Data are presented as mean (± standard deviation) for normally distributed variables and as median (inter-quartile range) for non-normally distributed variables
and as frequency (percentage) for categorical variables. Abbreviations: RMR resting metabolic rate, RQ respiratory quotient, VCO2 carbon dioxide produced, VO2
oxygen consumed, LTPAQ leisure time physical activity questionnaire, AMI activity metabolic index, PA physical activity.
a = significantly different from Group 1; b = significantly different from Group 2; c = significantly different from Group 3.
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sured by CRP, an acute-phase reactant secreted from the
liver in response to pro-inflammatory cytokines (TNF-α
and IL-6). Pro-inflammatory cytokines are secreted from
the visceral adipose tissue in response to infiltration by
macrophages to expanding adipose tissue and act on the
liver to stimulate gluconeogenesis, resulting in increased
production of hepatic glucose and consequently increased
pancreatic secretion of insulin leading to the development
of insulin resistance [33]. CRP levels >3 mg.L-1 are indica-
tive of chronic low-grade inflammation [14]. Therefore in
the current study, CRP values suggestive of low-grade in-
flammation (4.98 (3.46) mg.L-1) were observed in those
who were insulin resistant. These values are comparable
to those reported by Thomson and colleagues [1] who
described a mean high sensitivity CRP of 5.1 (5.3) mg.L-1
in an overweight cohort of breast cancer survivors. Inter-
estingly, in the present study mean CRP values did not
exceed the 3 mg.L-1 cut-point in any of the non-insulin re-
sistant groups. Among breast cancer survivors, significant
associations have been documented between acute inflam-
matory markers (CRP and serum amyloid A (SAA)) and a
number of anthropometric and lifestyle related prognostic
indicators including BMI, increasing waist circumference
and decreasing physical activity levels [34] in addition to
all-cause mortality following breast cancer [5].
Chronic inflammation may also adversely influence
lipid-lipoprotein profiles resulting in dyslipidemia [33].
Consequently, in the current study HDL-C was significantlylower and TG significantly higher in the insulin resistant
group compared to all other groups. There is a lack of
consensus regarding the presentation of dyslipidemia in
obese, insulin resistant adults. Nieves and colleagues [31]
reported in insulin resistant, non-obese individuals, that
the presentation of dyslipidemia could be explained by dif-
fering levels of visceral fat accumulation. In contrast, Piché
and colleagues [32] suggested that variations in the pres-
entation of dyslipidemia in centrally obese adults were
driven by insulin resistance. In the current study, only
those who were insulin resistant showed evidence of
dyslipidemia, however causality cannot be inferred.
It should be acknowledged that the HOMA-IR scores
observed in this study (mean 2.09 (range: 0.47 – 6.36)
were lower than observed in similar cohorts for example
the HEAL study which reported mean HOMA-IR scores
of 2.55 (range: 0.25 – 40.16) [3]. The HEAL study is a
multicentre, multiethnic trial based in the United States
of America. To the authors’ knowledge, the current
study is the first to examine metabolic characteristics in
an Irish cohort of breast cancer survivors. One of the
limitations of this cohort is a lack of diversity variables
such as BMI scores. The mean BMI of participants in
the current study was 27.02 (range 19.7-39.9) kg.m-2
compared to 27.3 (range 16.2 – 53.3) kg.m-2 in those
involved in HEAL [3]. While the mean values are com-
parable, the range and maximum values were lower in
the current study. As obesity is the predominant under-
lying cause of insulin resistance [35], the lower HOMA-
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uted to lower range of BMI values. The prevalence of
obesity in Ireland is increasing steadily [36], albeit at a
slower rate than observed in North America [37]. None-
theless, the metabolic and physiological health conse-
quences of obesity in Ireland are becoming increasingly
evident and there is a need for intervention to prevent
further decline.
A relationship between physical activity and metabolic
markers was not observed in the current study. This is
in contrast other studies in breast cancer survivors who
reported correlations between physical activity and sev-
eral metabolic variables including fasting insulin [28],
HOMA-IR [28], CRP [34], leptin [38], IGF-I [38] and
IGFBP-3 [38]. Furthermore habitual physical activity levels
did not vary between groups. Sedentary behaviour was
prevalent across each of these groups representing 50%
(Range: 44% in Group 1 to 54% in Group 3) of waking
hours. In contrast, moderate and vigorous intensity activ-
ity accounted for only 7% of waking hours (Range: 5% in
Group 3 to 10% in Group 1) with less than one-third of
any group achieving recommended physical activity
guidelines. It could be suggested that the high percent-
age of sedentariness made it difficult to identify differ-
ences between equally sedentary groups in this small
sample. These results, like others [7,28], represent the
extent of the problem of inactivity among breast cancer
survivors and may also represent the problem of in-
activity at population level. Recent reports suggest that
31% of adults globally are inactive (not achieving
recommended physical activity guidelines), with inactivity
levels highest in Europe and America and greatest
amongst women [39]. Excess sedentary behaviour is
particularly concerning among breast cancer survivors
however due to the association between physical inactivity
and prognosis. Physical activity undertaken following
breast cancer is associated with up to a 35% reduction in
all-cause mortality [19,40] while inactivity has been linked
to a four-fold increase in mortality risk [41].
RMR comprises the largest component of energy ex-
penditure and therefore is an essential determinant of en-
ergy balance. Mean RMR levels (1297.53 (203.13) jK.day-1
(equivalent to 1297.53 (203.13) kcal.day-1 in the current
study were comparable to those reported previously in a
similar cohort (1300 (183.9) kcal.day-1) [1]. In addition,
both absolute and adjusted RMR were significantly higher
in the insulin resistant group compared to all others and
demonstrated moderate-to-weak correlations with a num-
ber of metabolic variables. These results are consistent
with others which report that adjusted RMR is typically
increased in individuals with T2DM relative to healthy
counterparts [42,43]. Weyer and colleagues [18] sug-
gested that increases in RMR occur early in the develop-
ment of T2DM in conjunction with the development ofprogressive metabolic abnormalities including an in-
crease in gluconeogenesis and increased hepatic glucose
productions. In contrast, there is a lack of consensus as
to whether RMR is increased or decreased in individuals
with clinically defined MetSyn compared to metabolic-
ally healthy counterparts [44,45]. Despite the exclusion
of individuals with T2DM from the current study, re-
sults are consistent with the development of underlying
glucose dysregulation. In contrast, non-insulin resistant
groups with lower RMR values may be at risk of contin-
ued weight gain [46].
The aim of the current study was to identify known
modifiable prognostic risk factors that may respond
favourably to intervention to improve breast cancer sur-
vival. This evaluation did not compare findings to a
matched control group however it is highly likely that
the presented metabolic characteristics are comparable
to population norms. Population statistics suggest that
“normal” is characterised by obesity [37], inactivity [39]
and sedentariness [47]; factors which are all associated
with reduced breast cancer outcome and will contribute
to metabolic decline. The challenge therefore with re-
habilitation in the cancer context is the need for cancer
survivors to adopt health promoting lifestyle behaviours
which may be different from pre-diagnosis levels. Rehabili-
tation which focuses on a return to “normal” function or
baseline levels is no longer adequate. Therefore it is sug-
gested that metabolic screening to identify key modifiable
risk factors and inform exercise prescription in this cohort
may be more valuable than comparison to a matched con-
trol group.
Conclusions
In recent years there has been increasing evidence of a
relationship between increasing levels of obesity, and
metabolic dysfunction, with poorer breast cancer prog-
nosis [3-5,48], highlighting the importance of accurately
assessing metabolic disturbance among breast cancer
survivors. A greater understanding of the presentation of
metabolic dysfunction will inform the design of targeted,
outcome-specific weight-loss and physical activity inter-
ventions aimed at improving biomarkers of breast can-
cer risk. In the present study we defined the MetSyn
according to the most recent consensus statement [12],
and then compared metabolic profiles across groups
based on increasing levels of central obesity and the
presence or absence of insulin resistance. Results identify
that the insulin resistant group displayed alterations in
both measures of insulin-glucose homeostasis and CRP,
two significant predictors of breast cancer outcome
[3,5]. In addition, results show that increasing central
obesity in the absence of insulin resistance was not asso-
ciated with a greater deterioration in metabolic profile
when compared to lean controls, suggesting that the
Guinan et al. Nutrition Journal 2013, 12:99 Page 8 of 9
http://www.nutritionj.com/content/12/1/99assessment of insulin resistance is crucial in the assess-
ment of metabolic dysfunction for identifying potentially
prognostic characteristics. While physical activity was
not associated with differing levels of metabolic dysfunc-
tion, the high prevalence of sedentary time and low ad-
herence to physical activity guidelines is concerning.
Elevated RMR values in the insulin resistant group how-
ever are consistent with others which have shown that
RMR is increased in the presence of serious metabolic
dysfunction and glucose dysregulation. In breast cancer
survivors, a comprehensive assessment of metabolic dys-
function is required to identify profiles that may poten-
tially have greater prognostic significance and may inform
the design of future targeted exercise interventions.
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